Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice
Open Access
- 12 August 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (8) , 1834
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer-related death and presents the lowest 5-year survival rate of any form of cancer in the US. Only 20% of PDAC patients are suitable for surgical resection and adjuvant chemotherapy, which remains the only curative treatment. Chemotherapeutic and gene therapy treatments are associated with adverse effects and lack specificity/efficacy. In this study, we assess the oncolytic potential of immuno-oncolytic tanapoxvirus (TPV) recombinants expressing mouse monocyte chemoattractant protein (mMCP-1 or mCCL2) and mouse interleukin (mIL)-2 in human pancreatic BxPc-3 cells using immunocompromised and CD-3+ T-cell-reconstituted mice. Intratumoral treatment with TPV/∆66R/mCCL2 and TPV/∆66R/mIL-2 resulted in a regression in BxPc-3 xenograft volume compared to control in immunocompromised mice; mCCL-2 expressing TPV OV resulted in a significant difference from control at p < 0.05. Histological analysis of immunocompromised mice treated with TPV/∆66R/mCCL2 or TPV/∆66R/mIL-2 demonstrated multiple biomarkers indicative of increased severity of chronic, active inflammation compared to controls. In conclusion, TPV recombinants expressing mCCL2 and mIL-2 demonstrated a therapeutic effect via regression in BxPc-3 tumor xenografts. Considering the enhanced oncolytic potency of TPV recombinants demonstrated against PDAC in this study, further investigation as an alternative or combination treatment option for human PDAC may be warranted.Keywords
All Related Versions
Funding Information
- Western Michigan University (1R15CA156262-01, 999-872)
- Charles River Laboratories (1R15CA156262-01, 999-872)
This publication has 113 references indexed in Scilit:
- Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?Nuclear Medicine and Molecular Imaging, 2017
- Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapyMedical Oncology, 2017
- Current and future therapies for advanced pancreatic cancerJournal of Surgical Oncology, 2017
- T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumorsMedical Oncology, 2017
- Oncolytic viral therapy for pancreatic cancerJournal of Surgical Oncology, 2017
- Early detection of pancreatic cancer: Where are we now and where are we going?International Journal of Cancer, 2017
- Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude miceVirus Genes, 2016
- The Genome Sequence of Yaba-like Disease Virus, a YatapoxvirusVirology, 2001
- Human recombinant monocyte chemotactic protein and other c-c chemokines bind and induce directional migration of dendritic cells in vitroJournal of Leukocyte Biology, 1996
- Approximating the Shapiro-Wilk W-test for non-normalityStatistics and Computing, 1992